News Related to Acute Clostridioides Difficile Infection

Related coverage linked through entity extraction aliases.

Ibezapolstat Preserves Beneficial Microbiome in Multiply-Recurrent C. difficile, Acurx Data Show

Jul 14, 2026

Acurx Pharmaceuticals announced that ibezapolstat preserves beneficial gut microbes in multiply-recurrent C. difficile infection and outperforms standard antibiotics in biofilm killing. A pilot trial in rCDI is set to begin, with plans for FDA approval under the Limited Population Pathway if successful.

Acurx Launches Clinical Trial Program for Ibezapolstat in Recurrent C. difficile Infection

Mar 10, 2026

Acurx Pharmaceuticals announced a new clinical trial program for ibezapolstat in patients with recurrent C. difficile infection, building on Phase 2 results showing 96% clinical cure rates with no recurrence while sparing the gut microbiome.